Why the study?
Does vasopressin improve systolic arterial pressure and reduce catecholamine requirements in patients with milrinone-induced hypotension?
Does vasopressin improve systolic arterial pressure and reduce catecholamine requirements in patients with milrinone-induced hypotension?
Very low dose vasopressin effectively increases systolic blood pressure and reduces the need for catecholamine pressors in patients experiencing milrinone-induced hypotension.
Answers are grounded in this paper and cite their sources.
May support vasopressin in milrinone-induced hypotension; hypothesis-generating and requires prospective confirmation before practice change.
Objective To determine whether vasopressin could be effective in treating the hypotension associated with phosphodiesterase III inhibition. Phosphodiesterase III inhibitors are cardiotonic agents that increase myocardial contractility and decrease vascular smooth muscle tone. The vasodilatory effect can be profound, and the resulting hypotension frequently requires the administration of catecholamine pressors. Design Retrospective analysis of existing data. Setting The medical or surgical intensive care unit of Columbia-Presbyterian Medical Center. Patients Three consecutive patients receiving milrinone and requiring catecholamine pressors to maintain systolic arterial pressure of > or =90 mm Hg. Interventions Vasopressin was administered to the three patients. Measurements and main results Vasopressin (0.03-0.07 units/min) increased systolic arterial pressure from 90+/-4.7 to 130+/-2.3 mm Hg while reducing the administration of catecholamine pressors. Conclusions Vasopressin at very low doses appears to be an effective vasopressor for milrinone-induced hypotension.
No takes yet. Share an insight, caveat, or question.
Gold et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: